Withings rolled out a BodyFit smart scale that advertises special support for people on GLP-1 weight‑loss drugs.
The device measures weight, body‑fat percentage and raw impedance like its predecessors, but its app now tags data as “GLP‑1 friendly.” The company says the software adjusts goal recommendations for users of semaglutide or tirzepatide, and it syncs with popular health apps. The launch was accompanied by a soft launch event at a Manhattan gym, where influencers tried the scale alongside free smoothies.
If the scale’s algorithms actually compensate for the rapid water loss common with GLP‑1 therapy, users could see more realistic progress bars. That would matter because many on the drugs report misleading weight trends that affect motivation. However, Withings offers no clinical validation, and the adjustments seem to be a simple calorie‑budget tweak rather than a scientifically vetted model.
In short, the BodyFit adds a buzzword to an otherwise unchanged product, and only time will tell if the feature does more than look good on a press release.